Two additional fill-finish sites received clearance, shortening lead times in the US and EU markets.
Regulatory clearance for two additional fill-finish manufacturing sites is expected to ease supply bottlenecks that have constrained the roll-out of popular GLP-1 based obesity treatments.
The new capacity is coming online in the US and the EU, allowing drug makers to shorten lead times and expand access to patients who have been waiting on starter doses. Wholesaler inventories remain lean, but production is now expected to outpace prescription growth by the end of the quarter.
Analysts said the clearance removes a key overhang for the sector, though pricing and reimbursement discussions in Europe could still create volatility. Demand from cash-pay patients and employer-sponsored programmes continues to exceed even the most optimistic initial forecasts.
Competitors with rival molecules are racing to bring their own obesity therapies to market, but the first movers still hold a significant lead in clinical data and prescriber familiarity.